We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.

5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました！！評価はいかに？

Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.

ASCO2025の注目演題を取り上げ解説、ディスカッションしました！

Brian, Tom and Silke discuss their highlights form ASCO 2025

Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.